02012nas a2200277   4500000000100000008004100001260001300042653001200055653002300067653002300090653001200113653000900125653002400134653002500158653001600183100001500199700001300214700001000227700001200237245015400249856007800403300001100481490000700492520122100499022001401720       1992                            d  c1992 May10aAnimals10aBacterial Proteins10aBacterial Vaccines10aleprosy10aMice10aMice, Inbred BALB C10aMycobacterium leprae10aVaccination1 aGelber R H1 aMurray L1 aSiu P1 aTsang M00aVaccination of mice with a soluble protein fraction of Mycobacterium leprae provides consistent and long-term protection against M. leprae infection.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC257082/pdf/iai00029-0126.pdf  a1840-40 v603 a<p>Groups of BALB/c mice were vaccinated intradermally with either Freund's incomplete adjuvant (FIA) alone, 10(7) heat-killed Mycobacterium leprae organisms in FIA, or a number of fractions of M. leprae containing soluble and/or cell wall components. At 1, 3, 6, 9, and 12 months later, vaccinated mice were challenged in the right hind footpad with 5,000 live M. leprae organisms, and vaccine protection was assessed 6 to 8 months later, at the peak of M. leprae multiplication in the negative control (FIA alone), by the two-sample rank-sum test. In these studies, a cell wall fraction rich in peptidoglycan was consistently ineffective. Both heat-killed M. leprae and a fraction containing cell wall and fixed proteins generally protected when the interval between vaccination and challenge was 1 or 3 months but not subsequently. On the other hand, soluble proteins of M. leprae alone or in combination (with cell wall fractions) consistently (14 of 14 instances) afforded highly significant protection (P less than or equal to 0.01) at all challenge intervals up to 1 year after vaccination. These results suggest that the soluble protein fraction of M. leprae offers promise for a vaccine against leprosy.</p>  a0019-9567